DOCSLIB.ORG

Innovative Therapeutic Strategies in the Treatment of Meningioma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Innovative Therapeutic Strategies in the Treatment of Meningioma ANTICANCER RESEARCH 35: 6391-6400 (2015) Review Innovative Therapeutic Strategies in the Treatment of Meningioma GERARDO CARUSO1, SAMER K. ELBABAA2, PABLO GONZALEZ-LOPEZ3, VALERIA BARRESI4, MARCELLO PASSALACQUA1 and MARIA CAFFO1 1Neurosurgical Clinic, Department of Neuroscience, and 4Department of Human Pathology, University of Messina, Messina, Italy; 2Department of Neurological Surgery, Saint Louis University School of Medicine, Saint Louis, MO, U.S.A.; 3Department of Neurosurgery, University Hospital Alicante, Miguel Hernandez University School of Medicine, Alicante, Spain Abstract. Few medical options are available for progressive/ (NF2) on chromosome 22q12.2. This gene encodes the recurrent and atypical/anaplastic meningiomas. New merlin structural protein of the membrane. Typically, developments in chemotherapeutic options for meningiomas individuals with NFT2 develop multiple meningiomas. have been explored over the past decade. We review the more About 90% of meningiomas are classified according to the recent literature to recognize studies investigating recent World Health Organization (WHO) grading system as WHO medical and chemotherapeutic agents that have been grade I (2). This group includes meningothelial, fibroblastic experienced or are currently being tested for meningiomas. and transitional meningiomas. WHO grade I meningiomas Combination therapies affecting multiple molecular targets are generally defined as benign, but, for these histotypes, are currently opening up and present significant promise as recurrence rates are in the range of 7-20% and these have a adjuvant therapeutic options. However, there is an evident clear possibility of progression to higher grades. Atypical need for new molecular studies in order to better understand meningiomas WHO grade II include 5-15% of all the biology of meningiomas and, thus, to identify new and meningiomas (3). These lesions present recurrence rates of more specific therapeutic targets. 30-40% (3). Chordoid and clear cell meningiomas have an aggressive course, with a high rate of recurrence, and are Meningiomas are the most common primary intracranial classified as grade II (4). Anaplastic or malignant neoplasm, constituting over one-third of all brain tumors (1). meningiomas are classified as WHO grade III and account Meningiomas arise from arachnoidal cells of the for 1-3% of cases (3). Grade III tumors have higher leptomeninges and may occur wherever arachnoidal cells are frequencies of local invasion, recurrence, and metastasis. located. The origin of meningioma is yet to be determined. The treatment of choice for benign meningiomas is Certainly radiation therapy used in the treatment of brain represented by total surgical resection, resulting in prolonged tumors is associated with an increased risk of meningioma. disease-free survival (5). Conversely, atypical and malignant Moreover, the presence of progesterone and estrogen meningiomas frequently recur and are associated with a receptors denotes a possible link between the development shorter overall survival (6). Treatment options for recurrence of meningioma and sex hormones. Neurofibromatosis type 2 or incomplete resection include further surgery, conventional (NFT2) is an autosomal-dominant disorder characterized by external beam irradiation, stereotactic radiosurgery and mutations of the tumor suppressor gene neurofibromin 2 systemic therapies. To date, chemotherapies and hormonal therapies have had only a very limited role and have been shown to be generally ineffective. Radiation therapy or stereotactic radiosurgery is limited by radiation neurotoxicity, Correspondence to: Gerardo Caruso, MD, Via Consolare Valeria no. tumor size, and injury to adjacent vascular or cranial nerves. 1, 98124, Messina, Italy. Tel: +39 0902217167, Fax: +39 090693714, e-mail: [email protected] Over the past decades, the use of systemic therapies in the treatment of meningiomas has been the subject of intense Key Words: Meningioma, nanomedicine, surgery, targeted therapies, research and novel promising drugs with therapeutic treatment, review. potential are now being tested in an increased number of 0250-7005/2015 $2.00+.40 6391 ANTICANCER RESEARCH 35: 6391-6400 (2015) clinical trials. Recently nanomedicine, the application of Genes of histone cluster 1 on 6p, as well as genes cyclin B1 nanotechnology to health care, holds great promise for (CCNB1) and marker of proliferation Ki-67 (MKI67) were revolutionizing medical treatments, imaging, drug delivery, shown to be overexpressed in recurrent meningiomas (13, and tissue regeneration. Nanoparticle systems in cancer 14). More, chromosomal aberrations associated with higher- therapies provide better penetration of therapeutic and grade meningioma include 1p, 6q, 10p, 10q, 14q, and 18q diagnostic agents, and a reduced risk in comparison to (15). Other markers that have been reported to correlate with conventional treatments. By using nanotechnology, it is higher-grade meningioma include the B-cell lymphoma 2 possible to deliver the drug to the targeted tissue and release (BCL2) proto-oncogene, p53, p51, alterations in tumor- the drug at a controlled rate. suppressor genes, the apoptosis antigen 1 (FAS receptor or Herein, we review the current literature for therapeutic APO1) transmembrane protein, the extracellular matrix approaches for meningiomas. In particular, after discussing protein tenascin, and five novel meningioma-expressed the standard therapy for meningiomas, including surgery and antigens (15-17). Immunohistochemical staining with the radiation therapy, we focus on novel therapeutic strategies in MIB-1 antibody (Ki-67) has consistently correlated with the treatment of recurrent and malignant meningiomas, meningioma recurrence (18). Vascular endothelial growth highlighting the emerging role of targeted molecular factor (VEGF) has also been associated with recurrence due therapies. to increased neovascularization (19). Osteopontin, a factor regulating several processes in tumor progression, is more Current Treatments highly expressed in recurrent compared to non-recurrent meningiomas and in grade II compared with grade I Surgery. Meningiomas grow by expanding, leading to meningiomas (20). However, subtotal resection alone remains compression of the adjacent structures (7). For symptomatic common in practice, and in some series of patients with 10 or progressively enlarging meningiomas, complete surgical to 20 years of follow-up, the 5-, 10-, and longer than 15-year excision of the tumor bulk, and surrounding dural progression rates following subtotal resection were 37 to attachment, is recommended. Prognostic variables predictive 47%, 55 to 63%, and greater than 70%, respectively (21). of survival in patients with meningiomas include the extent of resection, histological grade, patient’s age, and tumor Radiation therapy. The role of surgery alone, especially for location. The completeness of surgical removal is an atypical and malignant meningiomas, can sometimes be important prognostic feature (8). The best accepted factor for unsuccessful. Factors considered in the decision to use prediction of recurrence is the Simpson grading system, radiation therapy include the extent of resection, grade, and which evaluates invasion of the venous sinuses, tumor histological subtype, as well as age (in the case of pediatric nodules in adjacent dura, and infiltration of bone by meningiomas). meningothelial cells as chief causes for recurrence (9). Several types of external-beam radiation exist, including Patients with a Simpson grade 1 (complete removal) modern approaches such as photon-based stereotactic meningioma have a 10-year recurrence rate of 9% compared radiosurgery and hypofractionated radiation therapy. to patients with a Simpson grade 3 (complete removal, Treatment plans may be directed to the remaining lesion without coagulation of dural attachment or resection of following subtotal resection, or the resection cavity plus a involved sinus or hyperostotic bone) meningioma, for whom margin of approximately 1 cm following gross total resection the 10-year recurrence rate is about 29%. Kinjo et al. of higher grade tumors. Preliminary observational studies classified a more extensive resection as “grade zero”, have demonstrated that immediate postoperative radiation requiring gross total resection of the primary, any improves the outcomes in patients with WHO grade II and hyperostotic bone, and all involved dura with a 2 cm dural III meningiomas (22). Aghi and colleagues, in a series of 108 margin (10). patients with atypical meningiomas who underwent gross More factors may represent probable causes of recurrence total resection, showed that immediate postoperative in meningiomas. Extent of tumor resection, histological type radiation reduces local tumor recurrence and improves and WHO grade, and brain invasion are prognostic factors of survival of patients (23). Radiation necrosis, exacerbation of meningioma recurrence. Sphenoid wing and parasagittal peritumoral edema and cranial nerve palsy are the principle meningiomas recur most frequently because of their location complications observed in patients undergoing radiation and sinus attachments. The presence of remaining therapy (22). meningotheliomatous cells on dural strips or the presence of neoplastic dural cells around the site of craniotomy, might be Radiosurgery. Radiosurgery can represent an effective reasons for recurrence (11, 12). The possibility of a primary or adjunctive treatment for grade I meningiomas
Load more

Recommended publications
  • MEDICAL Injectables & ONCOLOGY TREND REPORT™
    MEDICAL INJECTABLEs & ONCOLOGY TREND REPORT™ 2010 firsT edition ICORE HEALTHCARE www.ICOREHealthcare.com/Trends.AsPx letter to OuR readers 1 Injectable Drugs: Giving You the Data You Need It is my pleasure to present you with the 2010 ICORE For this first edition, we surveyed 60 medical, pharmacy, and Healthcare Medical Injectables & Oncology Trend clinical directors representing 146 million lives to get an understanding ReportTM. It is the first of what will be an annual of what payors are doing today and planning to do in the future to publication. The purpose of our investment in this manage the quality and cost of care for medical benefit injectables. report is straightforward: Back in 2003 when ICORE We then evaluated health plan medical benefit injectable claims such Healthcare first began assisting payors in managing that benchmarks and trends could be determined. medical injectables, no reference or benchmark data ICORE Healthcare’s mission has not changed in the past seven existed. Frankly, this has continued to be the case years: We serve as the center of medical injectable drug management. until the release of this report, since few, if any, benefit To this end, we believe this report is one additional resource to assist managers are able to review and assess medical benefit our customers, colleagues, and partners. injectable claims. I want to give special thanks to the Assessing medical injectable use, costs, and trends payors who served on our advisory is more critical now than ever, since five of the top board of this publication and 16 drugs in 2009 (based upon sales dollars) were who provided invaluable input specialty drugs, whereas it is expected that 11 drugs of into the report’s overall objective, the top 16 will be injectable or specialty products by content, and design.
    [Show full text]
  • Nimotuzumab, an Antitumor Antibody That Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding While Permitting the Active Receptor Conformation
    Published OnlineFirst July 7, 2009; DOI: 10.1158/0008-5472.CAN-08-4518 Experimental Therapeutics, Molecular Targets, and Chemical Biology Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation Ariel Talavera,1,2 Rosmarie Friemann,2,3 Silvia Go´mez-Puerta,1 Carlos Martinez-Fleites,4 Greta Garrido,1 Ailem Rabasa,1 Alejandro Lo´pez-Requena,1 Amaury Pupo,1 Rune F. Johansen,3 Oliberto Sa´nchez,5 Ute Krengel,2 and Ernesto Moreno1 1Center of Molecular Immunology, Havana, Cuba; 2Department of Chemistry, University of Oslo, Oslo, Norway; and 3Center for Molecular and Behavioral Neuroscience, Institute of Medical Microbiology, University of Oslo, Rikshospitalet HF, Oslo, Norway; 4Department of Chemistry, University of York, Heslington, York, United Kingdom; and 5Center for Genetic Engineering and Biotechnology, Havana, Cuba Abstract region of the EGFR (eEGFR), leaving the dimerization ‘‘arm’’ in Overexpression of the epidermal growth factor (EGF) receptor domain II ready for binding a second monomer (4, 5). It has been (EGFR) in cancer cells correlates with tumor malignancy and shown that the eEGFR adopts a ‘‘tethered’’ or inactive conformation poor prognosis for cancer patients. For this reason, the EGFR in the absence of EGF (6). In this characteristic conformation, has become one of the main targets of anticancer therapies. the dimerization arm is hidden by interactions with domain IV, Structural data obtained in the last few years have revealed whereas domains I and III remain separated. Thus, to adopt the the molecular mechanism for ligand-induced EGFR dimeriza- ‘‘extended’’ or active conformation observed in the crystal structure tion and subsequent signal transduction, and also how this of the complex with EGF (4), the receptor must undergo a major signal is blocked by either monoclonal antibodies or small conformational change that brings together domains I and III (6).
    [Show full text]
  • Targeted and Novel Therapy in Advanced Gastric Cancer Julie H
    Selim et al. Exp Hematol Oncol (2019) 8:25 https://doi.org/10.1186/s40164-019-0149-6 Experimental Hematology & Oncology REVIEW Open Access Targeted and novel therapy in advanced gastric cancer Julie H. Selim1 , Shagufta Shaheen2 , Wei‑Chun Sheu3 and Chung‑Tsen Hsueh4* Abstract The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in recent years. We have reviewed the recent data of clinical trial incorporating targeted agents, including inhibitors of angiogenesis, human epidermal growth factor receptor 2 (HER2), mesenchymal–epithelial transition, epidermal growth factor receptor, mammalian target of rapamycin, claudin‑18.2, programmed death‑1 and DNA. Addition of trastuzumab to platinum‑ based chemotherapy has become standard of care as front‑line therapy in advanced GC overexpressing HER2. In the second‑line setting, ramucirumab with paclitaxel signifcantly improves overall survival compared to paclitaxel alone. For patients with refractory disease, apatinib, nivolumab, ramucirumab and TAS‑102 have demonstrated single‑agent activity with improved overall survival compared to placebo alone. Pembrolizumab has demonstrated more than 50% response rate in microsatellite instability‑high tumors, 15% response rate in tumors expressing programmed death ligand 1, and non‑inferior outcome in frst‑line treatment compared to chemotherapy. This review summarizes the current state and progress of research on targeted therapy for advanced GC. Keywords: Gastric cancer, Targeted therapy, Human epidermal growth factor receptor 2, Programmed death‑1, Vascular endothelial growth factor receptor 2 Background GC mortality which is consistent with overall decrease in Gastric cancer (GC), including adenocarcinoma of the GC-related deaths [4]. gastroesophageal junction (GEJ) and stomach, is the ffth Tere have been several eforts to perform large-scale most common cancer and the third leading cause of can- molecular profling and classifcation of GC.
    [Show full text]
  • The Antibody Zalutumumab Inhibits Epidermal Growth Factor Receptor Signaling by Limiting Intra- and Intermolecular Flexibility
    The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility Jeroen J. Lammerts van Bueren*, Wim K. Bleeker*, Annika Bra¨ nnstro¨ m†, Anne von Euler†, Magnus Jansson†, Matthias Peipp‡, Tanja Schneider-Merck‡, Thomas Valerius‡, Jan G. J. van de Winkel*§, and Paul W. H. I. Parren*¶ *Genmab, 3508 AD, Utrecht, The Netherlands; †Sidec, SE-164 40 Kista, Sweden; ‡Division of Nephrology and Hypertension, Christian-Albrecht-University, 24105 Kiel, Germany; and §Immunotherapy Laboratory, Department of Immunology, University Medical Centre Utrecht, 3584 EA, Utrecht, The Netherlands Edited by Michael Sela, Weizmann Institute of Science, Rehovot, Israel, and approved February 7, 2008 (received for review October 8, 2007) The epidermal growth factor receptor (EGFR) activates cellular intervene in EGFR signaling, as reflected by two classes of pathways controlling cell proliferation, differentiation, migration, anti-EGFR drugs that are currently used clinically: tyrosine and survival. It thus represents a valid therapeutic target for kinase inhibitors (TKIs) and monoclonal antibodies (mAbs). treating solid cancers. Here, we used an electron microscopy-based TKIs represent small-molecule inhibitors that block EGFR- technique (Protein Tomography) to study the structural rearrange- kinase activity by binding to the ATP-binding pocket, thereby ment accompanying activation and inhibition of native, individual, abrogating downstream EGFR signaling. The effects of TKI EGFR molecules. Reconstructed tomograms (3D density maps) seem to be primarily related to enzyme inhibition. showed a level of detail that allowed individual domains to be For mAbs, the mechanisms of action are more diverse and discerned. Monomeric, resting EGFR ectodomains demonstrated their relative contribution to antitumor activity is still being large flexibility, and a number of distinct conformations were investigated.
    [Show full text]
  • Pearls and Forget-Me-Nots in the Management of Retinoblastoma
    POSTERIOR SEGMENT ONCOLOGY FEATURE STORY Pearls and Forget-Me-Nots in the Management of Retinoblastoma Retinoblastoma represents approximately 4% of all pediatric malignancies and is the most common intraocular malignancy in children. BY CAROL L. SHIELDS, MD he management of retinoblastoma has gradu- ular malignancy in children.1-3 It is estimated that 250 to ally evolved over the years from enucleation to 300 new cases of retinoblastoma are diagnosed in the radiotherapy to current techniques of United States each year, and 5,000 cases are found world- chemotherapy. Eyes with massive retinoblas- Ttoma filling the globe are still managed with enucleation, TABLE 1. INTERNATIONAL CLASSIFICATION OF whereas those with small, medium, or even large tumors RETINOBLASTOMA (ICRB) can be managed with chemoreduction followed by Group Quick Reference Specific Features tumor consolidation with thermotherapy or cryotherapy. A Small tumor Rb <3 mm* Despite multiple or large tumors, visual acuity can reach B Larger tumor Rb >3 mm* or ≥20/40 in many cases, particularly in eyes with extrafoveal retinopathy, and facial deformities that have Macula Macular Rb location been found following external beam radiotherapy are not (<3 mm to foveola) anticipated following chemoreduction. Recurrence from Juxtapapillary Juxtapapillary Rb location subretinal and vitreous seeds can be problematic. Long- (<1.5 mm to disc) term follow-up for second cancers is advised. Subretinal fluid Rb with subretinal fluid Most of us can only remember a few interesting points C Focal seeds Rb with: from a lecture, even if was delivered by an outstanding, Subretinal seeds <3 mm from Rb colorful speaker. Likewise, we generally retain only a small and/or percentage of the information that we read, even if writ- Vitreous seeds <3 mm ten by the most descriptive or lucent author.
    [Show full text]
  • Metabolic Profiling of the Three Neural Derived Embryonal Pediatric Tumors
    Metabolic profiling of the three neural derived embryonal pediatric tumors retinoblastoma, neuroblastoma and medulloblastoma, identifies distinct metabolic profiles Kohe, Sarah; Bennett, Christopher; Gill, Simrandip; Wilson, Martin; McConville, Carmel; Peet, Andrew DOI: 10.18632/oncotarget.24168 License: Creative Commons: Attribution (CC BY) Document Version Publisher's PDF, also known as Version of record Citation for published version (Harvard): Kohe, SE, Bennett, CD, Gill, SK, Wilson, M, McConville, C & Peet, AC 2018, 'Metabolic profiling of the three neural derived embryonal pediatric tumors retinoblastoma, neuroblastoma and medulloblastoma, identifies distinct metabolic profiles', OncoTarget, vol. 9, no. 13, pp. 11336-11351. https://doi.org/10.18632/oncotarget.24168 Link to publication on Research at Birmingham portal General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law. •Users may freely distribute the URL that is used to identify this publication. •Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research. •User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain. Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • Retinoblastoma
    A Parent’s Guide to Understanding Retinoblastoma 1 Acknowledgements This book is dedicated to the thousands of children and families who have lived through retinoblastoma and to the physicians, nurses, technical staf and members of our retinoblastoma team in New York. David Abramson, MD We thank the individuals and foundations Chief Ophthalmic Oncology who have generously supported our research, teaching, and other eforts over the years. We especially thank: Charles A. Frueauf Foundation Rose M. Badgeley Charitable Trust Leo Rosner Foundation, Inc. Invest 4 Children Perry’s Promise Fund Jasmine H. Francis, MD The 7th District Association of Masonic Lodges Ophthalmic Oncologist in Manhattan Table of Contents What is Retinoblastoma? ..........................................................................................................3 Structure & Function of the Eye ...........................................................................................4 Signs & Symptoms .......................................................................................................................6 Genetics ..........................................................................................................................................7 Genetic Testing .............................................................................................................................8 Examination Schedule for Patients with a Family History ........................................ 10 Retinoblastoma Facts ................................................................................................................11
    [Show full text]
  • The Erbb/HER Family of Protein-Tyrosine Kinases and Cancer
    Pharmacological Research 79 (2014) 34–74 Contents lists available at ScienceDirect Pharmacological Research jo urnal homepage: www.elsevier.com/locate/yphrs Invited Review The ErbB/HER family of protein-tyrosine kinases and cancer ∗ Robert Roskoski Jr. Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, NC 28742, USA a r t i c l e i n f o a b s t r a c t Article history: The human epidermal growth factor receptor (EGFR) family consists of four members that belong to the Received 7 November 2013 ErbB lineage of proteins (ErbB1–4). These receptors consist of a glycosylated extracellular domain, a sin- Accepted 8 November 2013 gle hydrophobic transmembrane segment, and an intracellular portion with a juxtamembrane segment, a protein kinase domain, and a carboxyterminal tail. Seven ligands bind to EGFR including epidermal This paper is dedicated to the memory of growth factor and transforming growth factor ␣, none bind to ErbB2, two bind to ErbB3, and seven lig- Dr. John W. Haycock (1949–2012) who ands bind to ErbB4. The ErbB proteins function as homo and heterodimers. The heterodimer consisting of prompted the author to write a review on the treatment of malignant diseases with ErbB2, which lacks a ligand, and ErbB3, which is kinase impaired, is surprisingly the most robust signaling targeted protein kinase inhibitors. complex of the ErbB family. Growth factor binding to EGFR induces a large conformational change in the extracellular domain, which leads to the exposure of a dimerization arm in domain II of the extracellular Chemical compounds studied in this article: segment.
    [Show full text]
  • Neurofibromatosis Type 1 and Type 2 Associated Tumours: Current Trends in Diagnosis and Management with a Focus on Novel Medical Therapies
    Neurofibromatosis Type 1 and Type 2 Associated Tumours: Current trends in Diagnosis and Management with a focus on Novel Medical Therapies Simone Lisa Ardern-Holmes MBChB, MSc, FRACP A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy Faculty of Health Sciences, The University of Sydney February 2018 1 STATEMENT OF ORIGINALITY This is to certify that this submission is my own work and that, to the best of my knowledge, it contains no material previously published or written by another person, or material which to a substantial extent has been accepted for the award of any other degree or diploma of the university or other institute of higher learning, except where due acknowledgement has been made in the text. Simone L. Ardern-Holmes 2 SUMMARY Neurofibromatosis type 1 (NF1) and Neurofibromatosis type 2 (NF2) are distinct single gene disorders, which share a predisposition to formation of benign nervous system tumours due to loss of tumour suppressor function. Since identification of the genes encoding NF1 and NF2 in the early 1990s, significant progress has been made in understanding the biological processes and molecular pathways underlying tumour formation. As a result, identifying safe and effective medical approaches to treating NF1 and NF2-associated tumours has become a focus of clinical research and patient care in recent years. This thesis presents a comprehensive discussion of the complications of NF1 and NF2 and approaches to treatment, with a focus on key tumours in each condition. The significant functional impact of these disorders in children and young adults is illustrated, demonstrating the need for coordinated care from experienced multidisciplinary teams.
    [Show full text]
  • High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody-Drug Conjugates Bart ECG De Goeij1, David Sa
    Author Manuscript Published OnlineFirst on February 27, 2015; DOI: 10.1158/1535-7163.MCT-14-0798 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. High turnover of Tissue Factor enables efficient intracellular delivery of antibody-drug conjugates Bart ECG de Goeij1, David Satijn1, Claudia M Freitag1, Richard Wubbolts2, Wim K Bleeker1, Alisher Khasanov3, Tong Zhu3, Gary Chen3, David Miao3, Patrick HC van Berkel1 and Paul WHI Parren1,4 1 Genmab, Yalelaan 60, 3584 CM, Utrecht, The Netherlands 2 Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 2, 3584 CM, Utrecht, The Netherlands 3 Concortis Biosystems Corp., San Diego, 11760 Sorrento Valley, CA 92121, USA 4 Dept. of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark Running title: Tissue Factor antibody-drug conjugate Key words: Tissue Factor, antibody-drug conjugate, internalization Corresponding author: Bart ECG de Goeij Genmab B.V. Yalelaan 60 3584CM Utrecht The Netherlands [email protected] +31 (0) 302123181 Conflict of interest statement: BECGG, DS, CMF, WKB, PHCB and PWHI are Genmab employees and own Genmab warrants and/or stock. 1 Downloaded from mct.aacrjournals.org on September 23, 2021. © 2015 American Association for Cancer Research. Author Manuscript Published OnlineFirst on February 27, 2015; DOI: 10.1158/1535-7163.MCT-14-0798 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Antibody drug conjugates (ADC) are emerging as powerful cancer treatments that combine antibody-mediated tumor targeting with the potent cytotoxic activity of toxins.
    [Show full text]
  • RETINOBLASTOMA Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines
    RETINOBLASTOMA Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines RETINOBLASTOMA Executive Summary Retinoblastoma is the most frequent neoplasm of the eye in childhood, and represents 3% of all childhood malignancies. It is a cancer of the very young; two-thirds are diagnosed before 2 years of age, and 95% before 5 years. For these reasons, therapeutic approaches need to consider not only the cure of the disease but also the need to preserve vision with minimal long-term side effects. The average age-adjusted incidence rate of retinoblastoma in the United States and Europe is 2-5/106 children (approximately 1 in 14,000 – 18,000 live births). However, the incidence of retinoblastoma is not distributed equally around the world. It appears to be higher (6-10/106 children) in Africa, India, and among children of Native American descent in the North American continent. 1 Whether these geographical variations are due to ethnic or socioeconomic factors is not well known. However, the fact that even in industrialized countries an increased incidence of retinoblastoma is associated with poverty and low levels of maternal education, suggests a role for the environment. 2,3 Retinoblastoma presents in two distinct clinical forms: (1) A bilateral or multifocal, heritable form (25% of all cases), characterized by the presence of germ-line mutations of the RB1 gene; and (2) a unilateral or unifocal form (75% of all cases), 90% of which are non-hereditary. The most common presenting sign of retinoblastoma is leukocoria, and some patients may also present with strabismus.
    [Show full text]